Team:Pasteur Paris/Entrepreneurship


Since we feel NeuronArch is a promising project in the field of biotechnology and prosthetics, we envisioned it as a startup company and designed a business plan accordingly to the experience we had this year participating at iGEM.

Even though leg prosthetics are becoming more and more efficient and sophisticated, allowing amputees to even participate to Olympic races, arm prosthetics have not evolved that much from the last century, usually equipped on the torso with a harness and are not so practical. While biomechanical prosthetics are slowly entering the market, bionic prosthetics are still missing because current technology does not allow a direct connection between the amputated limb’s nerves and the prosthetics itself. Osseointegrated prosthetics may be the field allowing this connection but the risk of infection by pathogenic biofilms on this type of interface is very high, requiring a heavy antibiotic treatment and removal of the osseointregrated prosthetic. To answer this problem, we used synthetic biology to create an engineered biofilm able to stimulate nerve regrowth after amputation but also reducing the risk of the formation of a pathogenic biofilm.

Figure 1: Year 2005, limb loss estimates by age (United States) [1] (A) Data on limb loss for people under and over 65. (B) Distribution of limb loss for people between 18 and 64. (C) Distribution of limb loss between 65 and 100. There is a discrepancy between sums and totals due to rounding. Values representing less than 1000 is indicated with a*.

Before bringing NeuronArch to an industrial level, we first evaluated our target market, depending on the number of amputation and realized that our device, which would mainly be used by young/active people, was aiming at only a minority of the amputations. In fact, 57% of amputees [1] are under 65 years old, and in this group, 66.5% are between the age of 45 and 64 years old, while only 30% are between the age of 18 and 44 years old (Cf. Figure 1).

2005 2010 2020 2050
Dysvascular Disease Total 846 969 1285 2272
Dysvascular Disease with Comorbidity of Diabetes 592 674 899 1667
Trauma 704 769 906 1326
Cancer 18 19 22 29
Total 1568 1757 2213 3627
Table 1: Expected occurrence of limb loss causes, from 2005 to 2050 in the United States [2].

Introduction of custom-made implant products (rising demands for advanced orthopedic prosthetics, favorable reimbursement for orthopedic prosthetics, rise in prevalence of lifestyle related diseases and disorders, growing focus on containment of healthcare costs and distribution & collaboration agreements to increase product reach driving global revenues) is creating high potential growth opportunities for players operating in global orthopedic prosthetics market. Spur in the disposable household income in the emerging economies are expected to provide ample opportunities to the manufacturers operating in the osseointegrated implants market.

We feel our interface NeuronArch could respond to this demand, and tried our best to tackle every issue that comes with trying to bring NeuronArch to the industrial scale.

In the Business Plan, that you can download here, you will find a Market Analysis, Study of possible competition by private companies, our Marketing Plan, our Sales Plan, our Operations, details on our Company, as well as our Financial Plan.


  • Kathryn Ziegler-Graham, Ellen J. MacKenzie, Patti L. Ephraim, Thomas G. Travison, Ron Brookmeyer. Estimating the Prevalence of Limb Loss in the United States: 2005 to 2050, Archives of Physical Medicine and Rehabilitation (2008). Volume 89, Issue 3, Pages 422-429.

  • Prescient Strategic Intelligence, “Osseintegration Implants Market” (2018) Retrieved Sep. 10th 2018 from